menu

News

Press Releases

January 30, 2025

Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics

January 3, 2025

Accelerating Bispecific Antibody Discovery: From Antigens to Lead Panels in Just Four Months

December 3, 2024

Invenra Unveils Rapid Bispecific Antibody Discovery Services – 4 Months from Start to Finish

September 17, 2024

Invenra Welcomes Three Industry Leaders to Its Board of Directors

August 23, 2024

Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment

August 8, 2024

Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

April 9, 2024

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery

April 2, 2024

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

August 16, 2021

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

October 31, 2019

Invenra Announces Expansion of Collaboration with Exelixis

January 31, 2019

Invenra and WARF Initiate a Collaboration to Discover and Develop Novel Therapeutics to Fight Neuroblastoma

May 2, 2018

Exelixis and Invenra Enter into Collaboration to Discover and Develop Novel Biologics to Treat Cancer

September 26, 2017

Invenra Adds Experienced Clinical Immuno-Oncologist Dr. Paul Sondel to Advisory Team

February 28, 2017

Invenra and QIMR Berghofer Medical Research Institute Enter Collaboration to Discover Therapeutic Antibodies

December 13, 2016

Invenra and AgonOx Enter into Collaboration to Discover Therapeutic Antibodies Against Novel Immuno-Oncology Target

June 15, 2015

Invenra and Oxford BioTherapeutics Enter into Collaboration to Discover Novel Therapeutic Antibodies Against Novel Cancer Target